IRLAB Therapeutics AB Class A
0.10
USD
- -
- -
Important Dates
IRLAB THERAPEUTICS AB's next confirmed earnings release is scheduled for November 13, 2026.
| Earnings Date | 11/13/2026 |
Share Statistics
As of June 30, 2026, IRLAB THERAPEUTICS AB has 84.94M shares outstanding.
| Shares Outstanding | 84.94M |
Financial Position
As of June 30, 2026, IRLAB THERAPEUTICS AB maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.55 |
| Quick Ratio | 0.40 |
| Debt / Equity | 24.92 |
Financial Efficiency
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 31.50 |
Balance Sheet
USDAs of June 30, 2026, IRLAB THERAPEUTICS AB holds 3.53M in cash and equivalents against 2.50M in total debt, resulting in a net debt position of -1.22M. Total book value stands at 10.02M, with working capital of 4.83M providing operational flexibility.
| Cash & Cash Equivalents | 3.53M |
| Total Debt | 2.50M |
| Net Debt | -1.22M |
| Equity (Book Value) | 10.02M |
| Book Value Per Share | 0.12 |
| Working Capital | 4.83M |
Stock Splits
IRLAB THERAPEUTICS AB's most recent stock split took place on June 8, 2026.
| Last Split Date | 6/8/2026 |